HBIO - Harvard Bioscience Inc Stock Price, Fair Value and News

$0.73+0.01 (+1.39%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HBIO Price Action

Last 7 days

-2.7%

Last 30 days

28.1%

Last 90 days

55.3%

Trailing 12 Months

-67.4%

HBIO RSI Chart

HBIO Valuation

Market Cap

32.5M

Price/Earnings (Trailing)

-0.6

Price/Sales (Trailing)

0.37

EV/EBITDA

-0.53

Price/Free Cashflow

4.37

HBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HBIO Fundamentals

HBIO Revenue

Revenue (TTM)

87.4M

Rev. Growth (Yr)

-6.27%

Rev. Growth (Qtr)

0.69%

HBIO Earnings

Earnings (TTM)

-53.8M

Earnings Growth (Yr)

74.36%

Earnings Growth (Qtr)

46.06%

HBIO Profitability

EBT Margin

-61.34%

Return on Equity

-382.68%

Return on Assets

-69.03%

Free Cashflow Yield

22.86%

HBIO Investor Care

Shares Dilution (1Y)

2.21%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	91.4M	88.8M	87.4M	0
2024	106.8M	101.1M	97.7M	94.1M
2023	114.5M	114.1M	112.5M	112.3M
2022	120.7M	120.7M	118.0M	113.3M
2021	105.3M	111.2M	116.8M	118.9M
2020	111.7M	105.5M	102.1M	102.1M
2019	122.2M	120.3M	119.1M	116.2M
2018	86.1M	98.6M	108.6M	120.8M
2017	95.6M	88.5M	82.2M	77.4M
2016	109.9M	107.2M	106.5M	104.5M
2015	108.5M	110.4M	110.7M	108.7M
2014	105.0M	105.8M	106.2M	108.7M
2013	108.9M	106.5M	105.6M	105.2M
2012	110.9M	112.2M	112.0M	111.2M
2011	108.2M	109.4M	109.4M	108.9M
2010	0	0	0	108.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.

CEO	Mr. James W. Green
WEBSITE	harvardbioscience.com
SECTOR	Healthcare
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	436

Harvard Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Harvard Bioscience Inc? What does HBIO stand for in stocks?

HBIO is the stock ticker symbol of Harvard Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harvard Bioscience Inc (HBIO)?

As of Wed Dec 03 2025, market cap of Harvard Bioscience Inc is 32.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HBIO stock?

You can check HBIO's fair value in chart for subscribers.

Is Harvard Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether HBIO is over valued or under valued. Whether Harvard Bioscience Inc is cheap or expensive depends on the assumptions which impact Harvard Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HBIO.

What is Harvard Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, HBIO's PE ratio (Price to Earnings) is -0.6 and Price to Sales (PS) ratio is 0.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Harvard Bioscience Inc's stock?

In the past 10 years, Harvard Bioscience Inc has provided -0.14 (multiply by 100 for percentage) rate of return.